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Abstract: Pulmonary rehabilitation is effective for improving exercise capacity in patients with interstitial lung disease (ILD), and most 
programs last about 8 weeks. A 43-year-old male patient with systemic sclerosis and oxygen saturation (SpO2) declining because of 
severe ILD was hospitalized for treatment of chronic skin ulcers. During admission, he completed a 27-week walking exercise program 
with SpO2 monitoring. Consequently, continuous walking distance without severe hypoxia (SpO2 . 90%) increased from 60 m to 300 m 
after the program, although his six-minute walking distance remained the same. This suggests that walking exercise for several months 
may reduce the risk of hypoxia in patients with ILD, even though exercise capacity does not improve.
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Introduction
Systemic  sclerosis  is  a  multisystem  disease  with 
pulmonary  involvement,  which  decreases  exercise 
capacity and is related to survival.1,2 Medication and 
exercise training have recently been shown to improve 
dyspnea, six-minute walking distance, maximum heart 
rate, and quality of life.3 Most training studies4,5 have 
been performed using 8-week programs based on pul-
monary rehabilitation used in the treatment of chronic 
obstructive pulmonary disease.6,7 This study was per-
formed to evaluate the effects of a rehabilitation pro-
gram including walking training over a 6-month period 
in a patient with systemic sclerosis and to determine 
any improvement in exercise capacity.
case Report
A 43-year-old male patient with systemic sclerosis 
and ILD was admitted with chronic ulceration of his 
fingers. He had been treated for 4 years with corticos-
teroids, and at a dose of 10 mg for the 4 months prior 
to presentation. His lifestyle was sedentary and he 
had refused home oxygen therapy. He lived indepen-
dently, including being able to drive. His Hugh-Jones 
grade was 3, ie, he was unable to keep up with healthy 
persons walking on the level, but was able to walk for 
one mile (1.6 km) or more at a slower speed.
On admission, forced vital capacity was 61.5% and 
carbon monoxide diffusion capacity (DLCO) was 29.8% 
of predicted. Blood gas analysis showed a PaO2 of 
74 mmHg and PaCO2 of 39 mmHg. Right ventricular 
systolic pressure was 39 mmHg and mean pulmonary 
artery pressure was 18 mmHg. His   six-minute   walking 
distance was 521 m, with oxygen saturation (SpO2) 
declining from 96% at rest to 72% at completion, 
determined using a handheld pulse oximeter with a 
reflectance sensor on the forehead. Perceived exer-
tion  increased  from  0  to  4  on  the  Borg  10  scale. 
  Walking distance without rest was 60 m when SpO2 
declined to 85%.
After admission to hospital, the corticosteroid dose 
was kept the same as before, but bosentan, sildenafil, 
and prostacyclin derivatives were added to treat the 
ulcers. The prostacyclin dose was increased during 
the first 8 weeks of admission, and then remained 
unchanged until discharge.
The rehabilitation program included walking train-
ing, training for leg muscle strengthening with a sand 
weight of 2.5 kg on the mat, and additional stretching 
exercise  for  the  fingers  because  of  sclerotic  skin 
changes. The total time spent exercising was about 
one hour per day on 5 days per week. The patient gave 
informed consent to these rehabilitation treatments 
before starting the program. On the first day of walk-
ing training, 60 m walking in one minute was per-
formed based on the first evaluation and was repeated 
with rest intervals of a few minutes. The total walking 
training time was 20 to 30 minutes per day. Training 
distance without rest increased when SpO2 was above 
90% during training.
Figure 1 shows the training walking distance start-
ing from 60 m, increasing gradually to 300 m after 
27 weeks of training. The six-minute walking   distance, 
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Figure 1. Following walking exercise, training distance (●) increased during the intervention period. Six-minute walking test (■) showed no marked 
changes, while end %Spo2 of the test (▲) improved.Reduced hypoxia risk in SSc after rehabilitation
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evaluated five times, was about 500 m, and perceived 
exertion in the fifth test also increased from 0 to 4 on 
the  Borg  scale,  while  the  end  value  of  SpO2  was 
increased. At discharge, when the finger ulcers had 
resolved, forced vital capacity was 59.8% and DLCO 
was 24.2% of predicted. Right ventricular systolic 
pressure was 36 mmHg and mean pulmonary artery 
pressure was 19 mmHg, suggesting little change in 
cardiopulmonary function.
Discussion
This patient showed no improvement in six-minute 
walking  distance.  In  COPD  patients,  the  minimal 
important  difference  for  a  six-minute  walking  dis-
tance test is 25 m,8 and was 22 m in this patient. One of 
the exclusion criteria for the six-minute walking test 
is an initial resting SpO2 , 90%.9 However, there are 
no clear criteria to discontinue the test in relation to 
low SpO2. The final SpO2 in this patient was 72%–80%, 
showing slight improvement, although these values 
were thought to be harmful to his circulation. Because 
this patient had no severe dyspnea during the six-
minute walking test, it was recommended that he con-
tinue  most  of  his  daily  activities  despite  the  low 
oxygen saturation which might have been causing his 
finger ulcers.
During training in ILD, Holland et al3 set the low-
est SpO2 to 85%. Progressive walking training was 
introduced by Nava10 in stepwise rehabilitation fol-
lowing acute respiratory failure. High-intensity inter-
val exercise training for COPD is effective in inducing 
peripheral muscle adaptation, with less dyspnea com-
pared with constant-load exercise.11 These studies are 
encouraging with regard to interval walking training 
(SpO2 . 90%) for ILD patients. Exercise training was 
beneficial to our patient in reducing the risk of hypoxia 
during walking up to 300 m. Thus, exercise training 
would be effective in improving safety, considering 
both hemodynamics and skin ulcer recurrence.
Some medications for pulmonary arterial hyper-
tension were added to treat the ulcers. Bosentan is 
reported to have no effect on the six-minute walking 
distance in idiopathic pulmonary fibrosis,12 whereas 
prostacyclin derivatives improved six-minute walk-
ing distance test in systemic sclerosis with pulmonary 
arterial hypertension.12 These medications for pulmo-
nary arterial hypertension did not improve cardiopul-
monary function nor exercise capacity in our patient.
conclusion
Generally, exercise training for lung disease is known 
to increase exercise capacity over 8 weeks. Although 
the six-minute walking distance in this patient was 
about 500 m and did not change after exercise train-
ing, the risk of hypoxia was remarkably reduced up to 
300 m of walking. This case report suggests a benefit 
of exercise training to ameliorate hypoxia in addition 
to improving exercise capacity.
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